|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||186.25 - 187.51|
|52-week range||163.30 - 264.40|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||24.05|
|Forward dividend & yield||1.97 (1.07%)|
|Ex-dividend date||25 Apr 2022|
|1y target est||N/A|
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with M
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.